Sequencing Analysis of SLX4/FANCP Gene in Italian Familial Breast Cancer Cases

Irene Catucci1,2, Mara Colombo2, Paolo Verderio3, Loris Bernard4, Filomena Ficarazzi1, Frederique Mariette1, Monica Barile5, Bernard Peissel6, Elisa Cattaneo6,7, Siranoush Manoukian6, Paolo Radice1,2*, Paolo Peterlongo1,2

1 IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy, 2 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 3 Unit of Medical Statistics and Biometry, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 4 Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy, 5 Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy, 6 Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 7 Medical Genetics, Department of Medicine, Surgery and Dentistry, Università degli Studi di Milano, Milan, Italy

Abstract

Breast cancer can be caused by germline mutations in several genes that are responsible for different hereditary cancer syndromes. Some of the genes causing the Fanconi anemia (FA) syndrome, such as BRCA2, BRIP1, PALB2, and RAD51C, are associated with high or moderate risk of developing breast cancer. Very recently, SLX4 has been established as a new FA gene raising the question of its implication in breast cancer risk. This study aimed at answering this question sequencing the entire coding region of SLX4 in 526 familial breast cancer cases from Italy. We found 81 different germline variants and none of these were clearly pathogenic. The statistical power of our sample size allows concluding that in Italy the frequency of carriers of truncating mutations of SLX4 may not exceed 0.6%. Our results indicate that testing for SLX4 germline mutations is unlikely to be relevant for the identification of individuals at risk of breast cancer, at least in the Italian population.

Introduction

Breast cancer is a heterogeneous disease that can be caused by genetic and non-genetic factors. Genetic susceptibility to breast cancer is due to a large spectrum of germline variants. A consistent fraction of familial cases is due to rare high-penetrance mutations in the BRCA1 and BRCA2 genes. Other high or moderate penetrance alleles have been identified in genes responsible for hereditary syndromes of which cancer predisposition is one of the features. Namely, these are TP53 causing the Li-Fraumeni syndrome, PTEN causing the Cowden syndrome, STK11 causing the Peutz-Jeghers syndrome, CDH1 causing diffuse gastric cancer and ATM causing ataxia telangiectasia [1], [2]. Fanconi anemia (FA) is another cancer susceptibility syndrome characterized by genome instability, congenital abnormalities and bone marrow failure. This recessive syndrome is genetically heterogeneous arising from mutations in one of at least 13 different FA genes (FANCA-C, D1, D2, E-G, I, J and L-N). In 2002, the discovery that BRCA2 and FANCD1 are the same gene, provided the first evidence of common genetic bases for breast cancer susceptibility and FA [3]. Subsequent studies reaffirmed this connection showing that truncating mono-allelic mutations in BRIP1/FANCG and PALB2/FANCM had a frequency of approximately 1% in familial breast cancer cases [4], [5]. Moreover, the newly ascertained FA gene RAD51C harbored a truncating mutation in 4/1,100 (0.5%) of familial breast cancer cases from Germany [6]. Very recently, bi-allelic truncating mutations of SLX4 were found in FA patients linked to previously identified FA genes [7], [8]. So far, while BRCA2, BRIP1, PALB2, and RAD51C are associated with high or moderate breast cancer risk, the impact of SLX4 on breast cancer remains to be measured. In this context, we sequenced the entire coding region and the intron-exon boundaries of SLX4 in 526 familial breast cancer cases from Italy.

Methods

Patients

The 526 female index cases included in this study were ascertained at the Medical Genetics Units of the Fondazione IRCCS Istituto Nazionale Tumori and the Istituto Europeo di Oncologia in Milan, from March 2003 to August 2008. All subjects, therein referred to as BRCAx cases, were probands of families fulfilling previously reported diagnostic criteria for hereditary breast/ovarian cancer, based on disease family history and age at disease onset [9], [10]. All index cases were confirmed to carry deleterious mutations or unclassified variants in BRCA1 or BRCA2 genes, following direct sequencing or denaturing high-performance liquid chromatography (DHPLC) analysis of all
coding exons and adjacent splice sites, as previously described [9]. All participants in this study signed an informed consent to the use of their biological samples for research purposes. This study was approved by the Ethic Committee of Fondazione IRCCS Istituto Nazionale Tumori, Milan.

Mutation screening
The mutation analysis was performed by single strand DNA sequencing using primers previously described [7], with the exception of primers for exons 5, 8, 12B-F, 13 and 15 that were re-designed. Sequences of these primers are available upon request.

All newly identified variants have been deposited in the Database of Short Genetic Variations (dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/).

Results and Discussion
In the 526 BRCAX cases, we identified several variants, but no one could be considered as a clear pathogenic mutation. A total of 81 different variants were found and none was truncating (Table S1). Of these variants, 35 were previously annotated in public databases including dbSNP [11], 1000 Genomes [12], and Exome Variant Server (http://evs.gs.washington.edu/EVS/) and reported with carrier frequency ≥1% in Caucasians and thus considered as likely neutral polymorphisms (Table S1). Of the 46 remaining variants, 29 were missense, 14 were silent, two were intronic and one was a 3-nucleotide in-frame deletion causing the loss of a single conserved amino-acid (p.Ile1195del). All 46 variants were analyzed in silico to study their potential impact on mRNA splicing using the following four programs: Berkeley Drosophila Genome Project [13], NetGene2 [14], [15], SplicePredictor [16], and GeneSplicer [17]. For all but two variants the majority of programs predicted no effect on splicing. The two variants were the c.833G>A, predicted by three programs to create a new donor splice site, and the c.5155T>A, predicted by two programs to abolish the physiological acceptor site of exon 15. These predictions were confirmed using an additional program (MaxEntScan) [18]. The 29 missense variants were studied in silico by PolyPhen-2 [19], SIFT [20] and SNP&GO [21] programs and only the p.Ser1719Tyr was classified as a variant with possibly pathogenic effect by all three programs.

Pathogenic mutations of the FA genes BRIP1, PALB2, and RAD51C have been identified in familial cases with frequencies of 1% to 2% [1], [6], [22]. The vast majority of them are truncating. In Italian breast cancer families, only PALB2 has been studied and truncating mutations were reported with frequencies ranging between 0.8 and 2.1% [23], [24], [25]. Therefore, the failure of identifying this type of mutations in SLX4 in a large set of BRCAX cases argues against its role as a breast cancer predisposing gene. In addition, if present, these mutations must be very rare in the Italian population. For our sample size of 526 in which no events (no carriers of truncating SLX4 mutations) have been observed, the upper limit of the 95% confidence interval of the event probability is 0.006. This indicates that a population frequency of truncating mutations greater than 0.6% would result in a probability of less than 5% of not finding at least one carrier in our sample set and, accordingly, that in the Italian population the frequency of carriers of truncating mutations of SLX4 may not exceed 0.6%.

We cannot exclude that some of the 81 non-truncating variants we found may be pathogenic or associated with increased risk of breast cancer. In particular, the c.833G>A, c.3583_3585delATT and the c.5155T>A variants were considered to have the higher theoretical probability of being pathogenic, based on in silico analyses or phylogenetic conservation. Additional studies, including in vitro transcript analyses and functional assays would be required to verify the impact of these mutations on gene functioning. In addition, these variants were very rarely observed in cases (<0,2%) and the assessment of their pathogenicity by case-control studies was not carried out, since it would have required a very large sample size. Segregation analysis was prevented by lack of additional family members. Finally, as another limit of this study, we cannot rule out SLX4 mutations not detectable by sequence analyses, including copy number alterations and gene rearrangements, could be present in our sample set.

Our data are in line with those from a small study in 52 German and Byelorussian hereditary breast cancer cases, where extensive genetic variation was shown with lack of any clear pathogenic mutation [26], providing evidence against impact of SLX4 on breast cancer risk in the tested populations. However, SLX4 might impact on breast cancer risk in populations such as Indians, Americans, and Northern Europeans, where the FA families with SLX4 truncating mutations originated from [7], [8].

In conclusion, no clear pathogenic mutations were found in 526 Italian BRCAX cases, supporting the hypothesis that SLX4 is unlikely to be a breast cancer gene. Moreover, our data indicated that truncating mutations of SLX4 are extremely rare, if not absent, in Italy. Consequently, although our approach might have missed pathogenic SLX4 alterations, we argue that at present testing for germine mutations in this gene is unlikely to be relevant for the identification of individuals at risk of breast cancer, at least in the Italian population.

Supporting Information
Table S1 Variants found in 526 BRCAX cases.

Acknowledgments
We thank all individuals who participated in this study.

Author Contributions
Conceived and designed the experiments: IC PR PP. Performed the experiments: IC FF FM. Analyzed the data: IC MC PV PR PP. Contributed reagents/materials/analysis tools: LB MB BP EC SM. Wrote the paper: PR PP.

References
1. Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Ann Rev Genomics Hum Genet 9: 321–345.
2. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4: 174–191.
3. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, et al. (2002) Biallelic germline mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 30: 1239–1241.
4. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, et al. (2006) Truncating mutations of the FA genes BRIP1, PALB2, and RAD51C have been identified in familial cases with frequencies of 1% to 2% [1], [6], [22]. The vast majority of them are truncating. In Italian breast cancer families, only PALB2 has been studied and truncating mutations were reported with frequencies ranging between 0.8 and 2.1% [23], [24], [25]. Therefore, the failure of identifying this type of mutations in SLX4 in a large set of BRCAX cases argues against its role as a breast cancer predisposing gene. In addition, if present, these mutations must be very rare in the Italian population. For our sample size of 526 in which no events (no carriers of truncating SLX4 mutations) have been observed, the upper limit of the 95% confidence interval of the event probability is 0.006. This indicates that a population frequency of truncating mutations greater than 0.6% would result in a probability of less than 5% of not finding at least one carrier in our sample set and, accordingly, that in the Italian population the frequency of carriers of truncating mutations of SLX4 may not exceed 0.6%.

We cannot exclude that some of the 81 non-truncating variants we found may be pathogenic or associated with increased risk of breast cancer. In particular, the c.833G>A, c.3583_3585delATT and the c.5155T>A variants were considered to have the higher theoretical probability of being pathogenic, based on in silico analyses or phylogenetic conservation. Additional studies, including in vitro transcript analyses and functional assays would be required to verify the impact of these mutations on gene functioning. In addition, these variants were very rarely observed in cases (<0,2%) and the assessment of their pathogenicity by case-control studies was not carried out, since it would have required a very large sample size. Segregation analysis was prevented by lack of additional family members. Finally, as another limit of this study, we cannot rule out SLX4 mutations not detectable by sequence analyses, including copy number alterations and gene rearrangements, could be present in our sample set.

Our data are in line with those from a small study in 52 German and Byelorussian hereditary breast cancer cases, where extensive genetic variation was shown with lack of any clear pathogenic mutation [26], providing evidence against impact of SLX4 on breast cancer risk in the tested populations. However, SLX4 might impact on breast cancer risk in populations such as Indians, Americans, and Northern Europeans, where the FA families with SLX4 truncating mutations originated from [7], [8].

In conclusion, no clear pathogenic mutations were found in 526 Italian BRCAX cases, supporting the hypothesis that SLX4 is unlikely to be a breast cancer gene. Moreover, our data indicated that truncating mutations of SLX4 are extremely rare, if not absent, in Italy. Consequently, although our approach might have missed pathogenic SLX4 alterations, we argue that at present testing for germine mutations in this gene is unlikely to be relevant for the identification of individuals at risk of breast cancer, at least in the Italian population.

Supporting Information
Table S1 Variants found in 526 BRCAX cases.

Acknowledgments
We thank all individuals who participated in this study.

Author Contributions
Conceived and designed the experiments: IC PR PP. Performed the experiments: IC FF FM. Analyzed the data: IC MC PV PR PP. Contributed reagents/materials/analysis tools: LB MB BP EC SM. Wrote the paper: PR PP.
8. Kim Y, Lach FP, Desetty R, Hansenberg H, Auerbach AD, et al. (2011) Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 43: 142–146.
9. Manoukian S, Prisel B, Pensotti V, Barile M, Cortesi L, et al. (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43: 601–606.
10. Catucci I, Yang R, Verderio P, Pizzamiglio S, Hessen L, et al. (2010) Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat 31: E1052–1057.
11. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308–310.
12. Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061–1073.
13. Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in Genie. J Comput Biol 4: 311–323.
14. Brunak S, Engelbrecht J,Knudsen S (1991) Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 229: 49–63.
15. Helbsgaard SM, Kornning PG, Teasle N, Engelbrecht J, Rouze P, et al. (1996) Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 24: 3459–3452.
16. Brendel V, Xing L, Zhu W (2004) Gene structure prediction from consensus spliced alignment of multiple ESTs matching the same genomic locus. Bioinformatics 20: 1157–1169.
17. Pertea M, Lin X, Salzberg SL (2001) GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res 29: 1185–1190.
18. Yeo G, Burge GB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11: 377–394.
19. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249.
20. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073–1081.
21. Calabrese R, Capriotti E, Farinelli P, Martelli PL, Casadio R (2009) Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat 30: 1237–1244.
22. Hollestelle A, Waielewski M, Martens JW, Schutte M (2010) Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 20: 266–276.
23. Papi L, Patignano AL, Congregati C, Piaceri I, Zanina I, et al. (2010) A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer 9: 181–185.
24. Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, et al. (2010) PALB2: a novel inactivating mutation in an Italian breast cancer family. Fam Cancer 9: 531–536.
25. Peterlongo P, Catucci I, Pasquini G, Verderio P, Peissel B, et al. (2010) PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat 126: 825–828.
26. Landwehr R, Bogdanova NV, Antonenkova N, Meyer A, Bremer M, et al. (2011) Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. Breast Cancer Res Treat 130: 1021–1028.